

Careprost Bimatoprost 0.03% is a sterile ophthalmic solution supplied in a 3ml dropper bottle. When prescribed for eyelash hypotrichosis, bimatoprost is applied to the upper eyelid margin to support the growth of longer, fuller and darker eyelashes.
Careprost is packaged as sterile eye drops and is originally indicated for reducing elevated pressure inside the eye. Its use along the upper eyelash line for eyelash hypotrichosis is an off-label use of this ophthalmic medicine.
Eyelash hypotrichosis describes eyelashes that are inadequate or sparse. Bimatoprost 0.03% has been studied for its ability to increase overall eyelash prominence, including eyelash length, thickness, fullness and darkness.
Careprost is not a cosmetic eyelash serum. It is a prescription ophthalmic medicine and should only be used for eyelash growth when this has been specifically prescribed following consultation.
Bimatoprost is a synthetic prostamide. The precise mechanism responsible for its effects on eyelashes has not been fully established. Available pharmacological evidence suggests that it increases the proportion of eyelash hairs in the active anagen growth phase and may extend the duration of that phase.
The resulting changes develop gradually through the natural eyelash growth cycle rather than producing an immediate cosmetic effect.
For eyelash hypotrichosis, the solution is applied to the skin of the upper eyelid margin at the base of the eyelashes. It is not deliberately instilled into the eye when being used for this purpose.
Do not apply Careprost to the lower eyelash line. Repeated contact with surrounding skin may cause unwanted hair growth outside the intended treatment area.
Applying bimatoprost more frequently than prescribed does not produce faster or greater eyelash growth. If an application is missed, continue with the next scheduled application rather than applying extra solution.
The effect of bimatoprost is gradual. In controlled clinical research involving a purpose-labelled bimatoprost 0.03% eyelash formulation, differences from the vehicle treatment were identified from approximately eight weeks, with the primary assessment conducted after 16 weeks.
These data concern bimatoprost 0.03% used specifically along the upper eyelid margin; they are not a direct comparative study of Careprost against other eyelash products. Individual response and the time at which changes become noticeable can vary.
The eyelash changes produced by bimatoprost are not considered permanent. After treatment is discontinued, eyelashes are expected to move gradually back towards their previous appearance over the following weeks to months as the natural eyelash growth cycle continues.
Possible effects associated with bimatoprost include:
Bimatoprost can lower intraocular pressure. Anyone using glaucoma medication, prostaglandin analogue eye drops or other treatment affecting eye pressure should disclose this during consultation.
Clinical advice should also be sought before continuing treatment following an eye infection, eye injury, eye surgery, a marked eyelid reaction or any sudden change in vision.
Careprost contains benzalkonium chloride, a preservative that can be absorbed by soft contact lenses. Contact lenses should be removed before application and should not be reinserted until at least 15 minutes afterwards.
Careprost is a 3ml sterile ophthalmic solution containing bimatoprost 0.03%, equivalent to 0.3mg per ml. It is packaged as an eye-drop medicine but may be prescribed off-label for eyelash hypotrichosis.
No. Careprost is a prescription ophthalmic medicine rather than a cosmetic eyelash serum. Its active ingredient is bimatoprost 0.03%.
Careprost is labelled as an ophthalmic solution for reducing elevated intraocular pressure. When Careprost is prescribed for eyelash hypotrichosis, this is an off-label use of the medicine.
Careprost and Latisse are different branded product presentations. Both are associated with bimatoprost 0.03%, but Careprost is packaged as sterile eye drops, whereas Latisse is purpose-labelled for upper-eyelid application in countries where it is authorised. The products should not be assumed to be identical solely because they contain the same active ingredient and strength.
When prescribed for eyelash hypotrichosis, it is applied only to the skin of the upper eyelid margin at the base of the eyelashes, using a new sterile single-use applicator for each eye.
No. Bimatoprost eyelash application is intended for the upper eyelid margin. Applying it to the lower eyelid can increase exposure to surrounding skin and the likelihood of unwanted hair growth or pigmentation.
The manufacturer’s Careprost presentation is a 3ml dropper bottle. Any separate application accessories included by the dispensing service will be identified with the supplied treatment. Only the sterile applicators specified for treatment should be used, and each applicator should be discarded after one eye.
The response is gradual and varies between individuals. Controlled research on bimatoprost 0.03% detected treatment differences from approximately eight weeks and assessed the main outcome at 16 weeks. Earlier results should not be assumed or guaranteed.
Eyelash changes are expected to diminish gradually after bimatoprost is discontinued. Over several weeks to months, the eyelashes usually return towards their previous appearance.
Increased brown pigmentation of the iris has been reported with bimatoprost and is likely to be permanent if it occurs. Eyelid-skin pigmentation is more likely to reduce after treatment is discontinued.
This product page concerns prescribed use along the upper eyelash line. Bimatoprost should not be applied to the eyebrows or another area unless that use has been specifically assessed and prescribed by a clinician.
Not without clinical review. Bimatoprost can affect intraocular pressure and may interact with the intended pressure-lowering effect of bimatoprost, latanoprost or other prostaglandin analogue eye treatments.
Bimatoprost solution is formulated for ophthalmic use, so accidental entry into the eye is not generally expected to cause harm. It should not, however, be deliberately instilled into the eye when prescribed for eyelash treatment. Persistent irritation, pain or visual disturbance requires clinical advice.
No. Careprost is a prescription medicine and is supplied only following consultation and an appropriate prescribing decision.
```